FIELD: medicine, virology, vaccines. SUBSTANCE: invention relates to preparing live anti-influenza intranasal vaccine for adults humans and children. Vaccine strain A/17/Pert/95/29(H1N1) is reassortant. Strain is obtained by breeding epidemic virus A/Pert/13/95(H1N1) with cold-adapted temperature-sensitive attenuation donor-virus A/Leningrad/134/ /17/57(H2N2). Strain A/17/Pert/95/29(H1N1) multiplicates actively in developing chicken embryos at optimal temperature 34 C and shows temperature-sensitivity and cold-adaptability. Reassortant inherited from epidemic virus two genes encoding surface proteins (hemagglutinin and neuraminidase) and from attenuation donor - six genes encoding nonglycosylated proteins. By antigenic properties the strain corresponds to the strain of virus A/Pert/13/95. Strain A/17/Pert/95/29(H1N1) does not show reactogenicity for adult humans at intranasal administration and corresponds to indices of immunogenicity. By biological properties and indices of reactogenicity the vaccine strain A/17/Pert/95/29(H1N1) corresponds to vaccine strains imposed by Pharmacopoeia article FS 42-299 VS-89 for live anti-influenza vaccine for intranasal use in adult humans. EFFECT: strain of virus indicated above, valuable properties of vaccine. 1 tbl
